Development of pulmonary fibrocystic disease in the upper lobes is a well recognised extraskeletal manifestation of ankylosing spondylitis but its pathogenesis is obscure.' 2 Although pulmonary fibrosis may occur in association with other collagen vascular diseases, a predilection for the upper lobes is unique to ankylosing spondylitis. The fibrocystic disease is usually asymptomatic; if symptoms develop, they are usually due to superimposed colonisation or infection by fungi or mycobacteria.' -3 In this report we describe a patient with ankylosing spondylitis and apical fibrocystic disease, who developed a progressive left upper lobe cavitating infiltrate with haemoptysis and was found to have bronchocentric granulomatosis. Rohatgi, Turrisi are not known. Despite colonisation by a few branching hyphae and the presence of bronchial symptoms of purulent sputum and haemoptysis, our patient never showed eosinophilia or features of bronchoconstriction and thus cannot be categorised as having the asthmatic clinical form of bronchocentric granulomatosis. We believe that it was closer to the non-asthmatic form because of his age, bronchial symptoms, negative skin test responses to Aspergillus antigens, and the absence of clinical features of asthmatic type.
We have described a case of bronchocentric granulomatosis in a patient with apical fibrocystic disease associated with ankylosing spondylitis. Although there is no proof of a direct relationship, the simultaneous occurrence of these two rare diseases in the same person and the association of both diseases with Aspergillus is compelling. Possibly fibrocystic disease impaired the local defences of the lung and permitted colonisation of the airways with Aspergillus. The diffusion of antigens from the Aspergillus organisms may have produced a granulomatous hypersensitivity reaction in the airways. 
